Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00532064|
Recruitment Status : Completed
First Posted : September 19, 2007
Last Update Posted : May 8, 2018
-To determine if specific biomarkers (Troponin I and B-type natriuretic peptide [BNP]) detect cardiotoxicity earlier than standard clinical means in patients receiving Sunitinib Malate (SU11248) or Sorafenib chemotherapy.
-To prospectively evaluate the incidence and severity of cardiac toxicity related to sunitinib or sorafenib during chemotherapy.
|Condition or disease||Intervention/treatment|
|Advanced Cancers||Behavioral: Questionnaire|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||55 participants|
|Official Title:||Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers|
|Actual Study Start Date :||September 12, 2007|
|Actual Primary Completion Date :||May 2, 2018|
|Actual Study Completion Date :||May 2, 2018|
Early Cardiotoxicity Detection
Patients with advanced cancer receiving sunitinib malate or sorafenib chemotherapy.
Symptom questionnaire taking about 10-15 minutes.
Other Name: Survey
- Sensitivity of biomarkers for detecting cardiotoxicity [ Time Frame: Monthly ]The BNP and Troponin reassessed at 2 weeks and then each time blood is obtained for safety purposes during chemotherapy (approximately every 4-6 weeks); then data used to determine if specific biomarkers (Troponin I and B-type natriuretic peptide [BNP]) detect cardiotoxicity earlier than standard clinical means in patients receiving Sunitinib Malate (SU11248) or Sorafenib chemotherapy.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00532064
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Elie Mouhayar, MD||M.D. Anderson Cancer Center|